-
Product Insights
New![]()
Net Present Value Model: Inovio Pharmaceuticals Inc’s INO-5401
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Inovio Pharmaceuticals Inc's INO-5401 Drug Details: INO-5401 is under development for the treatment of newly diagnosed glioblastoma multiforme. The therapeutic candidate consist of three...
-
Product Insights
New![]()
Net Present Value Model: Inovio Pharmaceuticals Inc’s INO-3107
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Inovio Pharmaceuticals Inc’s (Bizalimogene ralaplasmid + Mavilimogene ralaplasmid)
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Inovio Pharmaceuticals Inc – Company Profile
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL, INO-5401 for glioblastoma, and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Takeda Pharmaceutical Co Ltd’s Cebsulfase alfa
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Dirloctocogene Samoparvovec
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Vera Therapeutics Inc’s MAU-868
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
NewNeedle Free Injections Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Needle Free Injections Pipeline Market Report Overview Needle free Injections are devices that do not use a needle to administer medication. The Needle Free Injections pipeline market research report provides comprehensive information about the Needle Free Injections pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Territories ·      The US ·      Europe ·      Mexico ·      The UK ·      Canada ·      Costa Rica ·      El...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SEFA-1024 in Hypertriglyceridemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SEFA-1024 in Hypertriglyceridemia Drug Details: SEFA-1024 is under development for the treatment of hypertriglyceridemia....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SV-102 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SV-102 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:SV-102 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Epilepsy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Epilepsy Drug Details: Everolimus is under development for the treatment of intractable...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid) in Vulvar Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid) in Vulvar Cancer Drug Details: VGX-3100 (a fixed dose combination of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INO-3107 in Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. INO-3107 in Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) Drug Details: INO-3107 is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Descartes-08 in Myasthenia Gravis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Descartes-08 in Myasthenia Gravis Drug Details:Descartes-08 is under development for the treatment of multiple myeloma (third-line...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INO-6145 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.INO-6145 in Human Immunodeficiency Virus (HIV) Infections (AIDS)Drug Details:INO-6145 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid) in Human Papillomavirus (HPV) Associated Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid) in Human Papillomavirus (HPV) Associated Cancer Drug Details: VGX-3100 (a...
-
Track & Monitor
New![]()
Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INOA-002 in Dengue Fever
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INOA-002 in Dengue Fever Drug Details:INOA-002 is under development for the treatment of Zika virus infections,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INO-5151 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INO-5151 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:INO-5151 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Telisotuzumab Vedotin in Squamous Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Telisotuzumab Vedotin in Squamous Non-Small Cell Lung Cancer Drug Details:Telisotuzumab vedotin (ABBV-399, ABT-399) is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.